Taysha gene therapies reports second quarter 2022 financial results and provides corporate update

Tsha-120 treated patients in gan demonstrated durable improvement and recoverability of sensory nerve amplitude potential (snap), a definitive clinical endpoint, compared to natural history
TSHA Ratings Summary
TSHA Quant Ranking